Aegis reiterated their buy rating on shares of Intelgenx Technologies (CVE:IGX) in a report released on Monday morning.
Intelgenx Technologies (CVE:IGX) opened at C$1.06 on Monday. The stock has a market capitalization of $68.07, a PE ratio of -35.33 and a beta of -0.04. Intelgenx Technologies has a fifty-two week low of C$0.78 and a fifty-two week high of C$1.39.
Intelgenx Technologies (CVE:IGX) last issued its quarterly earnings data on Thursday, November 9th. The company reported C($0.01) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of C($0.01).
TRADEMARK VIOLATION NOTICE: “Intelgenx Technologies (IGX) Given “Buy” Rating at Aegis” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/01/intelgenx-technologies-igx-given-buy-rating-at-aegis.html.
Intelgenx Technologies Company Profile
IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The companys products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2012 for schizophrenia; and INT0043/2015 to treat mild cognitive impairment and Alzheimers disease.
Receive News & Ratings for Intelgenx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intelgenx Technologies and related companies with MarketBeat.com's FREE daily email newsletter.